olezarsen investigational
Selected indexed studies
- Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. (Am Heart J, 2025) [PMID:40064331]
- Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: Results from a randomized trial. (Eur J Prev Cardiol, 2025) [PMID:40735960]
- Molecular Therapeutics in Development to Treat Hyperlipoproteinemia. (Mol Diagn Ther, 2025) [PMID:39875700]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. (2025) pubmed
- Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: Results from a randomized trial. (2025) pubmed
- Molecular Therapeutics in Development to Treat Hyperlipoproteinemia. (2025) pubmed
- Olezarsen and Beyond: Emerging Targeted Treatments for Familial Chylomicronemia Syndrome and Related Triglyceride Disorders. (2026) pubmed
- Safety and efficacy of therapies for chylomicronemia. (2022) pubmed
- Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors. (2026) pubmed